Systemic amyloid light-chain (AL) amyloidosis, a disease with improving outcomes using novel therapies, is increasingly recognized in the elderly, but treatment and outcomes have not been systematically studied in this group of patients. Here, Giampaolo Merlini, MD, from the University of Pavia, Paiva, Italy, discusses the clinical profile and treatment outcomes of this patient population, from an analysis conducted by his group. Dr Merlini highlights the most effective treatment approach indicated by this data. This video was recorded at the 2018 European Myeloma Network (EMN) Meeting, in Turin, Italy.
Treatment outcomes of elderly patients with AL Amyloidosis
